Previous close | 287.52 |
Open | 288.57 |
Bid | 285.04 x 900 |
Ask | 285.17 x 2200 |
Day's range | 283.89 - 291.01 |
52-week range | 187.16 - 311.88 |
Volume | |
Avg. volume | 1,206,619 |
Market cap | 41.751B |
Beta (5Y monthly) | 0.17 |
PE ratio (TTM) | 14.73 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
When the Food and Drug Administration (FDA) rejects a key drug from a healthcare company, it can send the stock spiraling into a sell-off. In order for the FDA to be confident in a drug's effectiveness, it needs to have a large enough sample size to evaluate it. Unfortunately, in Eli Lilly's case, it simply didn't have enough data points for the agency to make a positive conclusion about the treatment and grant it accelerated approval.
Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day.
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.